Based on the FIGHT-202 trial, the US Food and Drug Administration (FDA) has recently approved pemigatinib for previously treated ICC with FGFR2 fusions or rearrangements [82]. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.